How to retain healthcare corporate development leaders during M&A slowdowns

Your healthcare corporate development leaders are taking recruiter calls right now. Even in high-performing private equity portfolio companies, that reality has become difficult to ignore.

The slowdown in healthcare M&A activity throughout 2025 reshaped how corporate development leaders view their own trajectory. Without new deals to keep building their résumés, even the most committed leaders are quietly opening LinkedIn and reassessing what comes next.

While 2026 has shown early signs of recovery and the market is beginning to hint at renewed exit activity, that optimism has not yet translated into daily engagement for many healthcare corporate development teams.

Services and insurance platforms, for example, are still actively consolidating fragmented markets, which creates a steadier cadence of smaller transactions alongside larger platform plays. For leaders whose careers depend on repetition and range, those environments are increasingly attractive because they provide both volume and variety.

Healthcare-focused private equity firms cannot afford to wait for the market to correct itself. Retention at the corporate development level requires deliberate action.

Align career pathing to retain corporate development talent

Preemptive career conversations with corporate development leaders can reveal the best method of retention.

Most leaders in this function are working toward one of three destinations: CDO, CFO or president. Each path requires a distinct set of experiences.

If you figure out which path your corporate development leaders are striving for, tailor their current role to match that trajectory and continue supporting them throughout their career journey, they will be more inclined to stick with your firm through the exit lull.

Developing future CDOs through deal ownership and strategy

For those pursuing the chief development officer track, breadth and ownership are critical.

These leaders need experience with full lifecycle accountability. That includes leading service line expansion efforts and shaping partnership strategy in ways that influence long-term enterprise value.

In healthcare, this often means evaluating adjacency plays such as outpatient expansion, value-based care capabilities or technology-enabled services that enhance margin and differentiation.

It also means taking ownership of the process from initial diligence through integration, with clear visibility into how each transaction performs over time. Integration is where value is realized or lost, yet many corporate development leaders are removed from that phase too early. Extending their involvement allows them to refine their judgment and build pattern recognition across multiple deals.

Preparing corporate development leaders for CFO responsibilities

For those on a path toward the CFO seat, financial ownership must become part of their day-to-day reality.

These leaders need to understand how decisions translate into performance across a healthcare platform that is often balancing reimbursement pressure, labor costs and regulatory complexity. Giving them responsibility over a P&L, even at a divisional level, begins to close that gap.

It allows them to connect capital allocation decisions with operational outcomes, which is essential for any future finance leader. More importantly, it exposes them to the cadence of forecasting, budgeting and variance management, all of which require a different mindset than deal execution.

In many cases, this also means involving them in lender conversations, board reporting and audit processes. That level of exposure builds credibility and prepares them to step into a role where scrutiny is constant and precision is expected.

Building operations knowledge for future healthcare presidents

For those who aspire to be president of a sponsor-backed healthcare company, they must step into the operational fabric of the business.

This path requires time spent with commercial teams, with operations leaders and with functional heads who are responsible for delivering results.

That may include direct exposure to clinical operations, revenue cycle performance or site-level leadership where day-to-day decisions have immediate financial impact.

Without that experience, the transition from dealmaker to operator becomes significantly more difficult. Creating structured opportunities for operational ownership allows these leaders to build the judgment and resilience required for the role they ultimately want.

Why corporate development leaders leave and how to retain them

Corporate development leaders are far less likely to leave during an M&A slowdown when their role extends beyond the deal itself.

When transaction volume drops, highly capable leaders begin to question whether they are still developing. If their work is limited to live deals, a slower market can feel like stalled career momentum.

Broader experience helps solve that problem. When corporate development leaders are given exposure to integration, operations, financial management and strategic planning, they continue building relevant leadership muscle even when the market is quiet.

For private equity firms, the implication is clear: If you want to reduce attrition during slower M&A periods, do not wait for the market to improve. Expand the role now.